Equities researchers at HC Wainwright cut their FY2025 earnings per share (EPS) estimates for Vericel in a report issued on ...

Equities research analysts at HC Wainwright dropped their Q1 2025 earnings estimates for MoonLake Immunotherapeutics in a ...

Fintel reports that on February 26, 2025, HC Wainwright & Co. upgraded their outlook for Arcus Biosciences (NYSE:RCUS) from ...

Fintel reports that on February 27, 2025, HC Wainwright & Co. downgraded their outlook for LAVA Therapeutics N.V.

LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...

H.C. Wainwright downgraded Geron (GERN) to Neutral from Buy without a price target following the Q4 report. The shift in guidance for interim ...

Pemgarda has a standing emergency use authorization as a prophylaxis for immunocompromised patients, but FDA’s stringent ...

Highlights,Adjusted Q1 2025 EPS projections for Bausch + Lomb as analysts slightly reduce expectations.,Diverse analyst ...

Fintel reports that on February 24, 2025, HC Wainwright & Co. initiated coverage of Veritone (NasdaqGM:VERI) with a Buy recommendation. As of February 19, 2025, the average one-year price target ...

Highlights,HC Wainwright increased Coinbase Global’s price target, reflecting ongoing market evaluations.,Financial firms have issued mixed ratings, contributing to a diverse market ...

Precision BioSciences, Inc. (NASDAQ:DTIL) revealed initial results from the first administration of PBGENE-HBV in cohort 1, ...